Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Denis Platel"'
Publikováno v:
Pharmacology & Toxicology. 88:250-254
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::180c40d29ccf238829f27a8689e2f2ff
https://doi.org/10.1111/j.1600-0773.2001.880505.x
https://doi.org/10.1111/j.1600-0773.2001.880505.x
Publikováno v:
Toxicology Letters. 161:37-42
We have studied the protective effect of dexrazoxane on the cardiac toxicity induced by the anthracyclines currently used in clinics, doxorubicin, epirubicin, daunorubicin and idarubicin, with special emphasis on determining the optimal dose of dexra
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::979fa9e3b9433cb9ac32ab485cf4e771
https://doi.org/10.1016/j.toxlet.2005.07.013
https://doi.org/10.1016/j.toxlet.2005.07.013
Autor:
Corinne Rocher, Denis Platel, Yves Bourne, Klaus-Jörg Rieger, Jacques Winter, Paul Ferrari, Claire Senay
Publikováno v:
Journal of Biological Chemistry. 278:48395-48403
The formation of the Mtr2-Mex67 heterodimer is essential for yeast mRNA export as it constitutes a key nuclear component for shuttling mRNA between the nuclear and cytoplasm compartments through the nuclear pore complex. We report the crystal structu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0bf08a73cf18a29c67c9358dbf33fbcf
https://doi.org/10.1074/jbc.m308275200
https://doi.org/10.1074/jbc.m308275200
Comparative cardiotoxicity of idarubicin and doxorubicin using the isolated perfused rat heart model
Publikováno v:
Anti-Cancer Drugs. 10:671-676
Attempts to reduce the incidence of congestive heart failure following anthracycline therapy include the replacement of the parent compounds (especially doxorubicin) by less cardiotoxic analogs. Among these analogs, idarubicin (4-demethoxy-daunorubic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5174ee11ea60eb9609ddcb02ca3da05a
https://doi.org/10.1097/00001813-199908000-00007
https://doi.org/10.1097/00001813-199908000-00007
Autor:
Jean-Michel Bruneau, Thérèse Stachyra, Christine Miossec, Anne-Marie Girard, Monique Claudon, Denis Platel, Michael T. Black
Publikováno v:
Antimicrobial agents and chemotherapy. 52(9)
NXL101 is one of a new class of quinoline antibacterial DNA gyrase and topoisomerase IV inhibitors showing potent activity against gram-positive bacteria, including methicillin- and fluoroquinolone-resistant strains. NXL101 inhibited topoisomerase IV
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a761a36e80317f9423a6cc5ae5b72b53
https://pubmed.ncbi.nlm.nih.gov/18625781
https://pubmed.ncbi.nlm.nih.gov/18625781
Autor:
Gian Sberna, Jin Yu, Jill Bernays, Simon P. B. Ovenden, Dominique Lebeller, Larissa J. Christophidis, Soo San Wan, R. Murray Tait, Howard G. Wildman, Barbara M. Meurer-Grimes, Denis Platel, Tom W. May
Publikováno v:
Journal of Natural Products. 68
To new triterpenes, trichomycins A (1) and B (2), were purified from the new species Tricholoma sp. AU1 by activity-guided fractionation following their antibacterial activity. The two compounds were found to have a hitherto unreported triterpenoid s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3c61752dbab393ebc4599e068fc14abc
https://doi.org/10.1021/np058102w
https://doi.org/10.1021/np058102w
Autor:
Simon P B, Ovenden, Jin, Yu, Jill, Bernays, Soo San, Wan, Larissa J, Christophidis, Gian, Sberna, R Murray, Tait, Howard G, Wildman, Dominique, Lebeller, Denis, Platel, Tom W, May, Barbara M, Meurer-Grimes
Publikováno v:
Journal of natural products. 68(3)
To new triterpenes, trichomycins A (1) and B (2), were purified from the new species Tricholoma sp. AU1 by activity-guided fractionation following their antibacterial activity. The two compounds were found to have a hitherto unreported triterpenoid s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::4862f9e948cf29137966dbab8302b904
https://pubmed.ncbi.nlm.nih.gov/15787446
https://pubmed.ncbi.nlm.nih.gov/15787446
Publikováno v:
Scopus-Elsevier
Cardiotoxicity is the major side-effect and limits the clinical use of the anthracyclines, doxorubicin and daunorubicin. A special problem is raised by the metabolites of these drugs, the amount of which may vary according to drug combinations and fo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6b629ded10c256f13c42bed6f3505269
https://pubmed.ncbi.nlm.nih.gov/11393585
https://pubmed.ncbi.nlm.nih.gov/11393585
Publikováno v:
Toxicology and applied pharmacology. 163(2)
Paclitaxel strongly potentiates the cardiotoxicity of doxorubicin in the clinical setting. In this study, we aimed (1) to determine whether this potentiation could be reproduced in an ex vivo model and, if so, (2) to select drugs and protocols that d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c81fdc75d684a4aca35e7f2829dd686d
https://pubmed.ncbi.nlm.nih.gov/10698671
https://pubmed.ncbi.nlm.nih.gov/10698671